AnaptysBio raises $40m for Phase II studies

San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.